Director/PDMR Shareholding

RNS Number : 7005I

Mediclinic International plc

15 December 2020

 

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

South African income tax number: 9432434182

("Mediclinic", the "Company", or the "Group")

15 December 2020

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Awards under the Company's Long-Term Incentive Plan

As disclosed in the Directors' Remuneration Report of 1 June 2020 for the year ending 31 March 2020 (the "FY20 DRR"), Mediclinic's Remuneration Committee had intended to disclose prospectively  the performance metrics for awards granted during the current financial year ("FY21") under the Company's Long-Term Incentive Plan (the "LTIP"). However, given the uncertainty presented by the COVID-19 pandemic (the "pandemic") and the difficulties associated with setting meaningful targets at the time, the Committee communicated that it had chosen to defer a decision on these metrics and levels of any awards made under the LTIP (typically granted in June) until later during FY21. The Committee debated these at length in recent months and, in line with the commitments made in the FY20 DDR, has consulted with major shareholders in advance of concluding on the matter.

Taking into consideration feedback received from shareholders, the Committee has now decided to approve the awards and corresponding metrics set out below.

Awards granted under the Company's Long-Term Incentive Plan

On 14 December 2020, awards over ordinary shares in Mediclinic ("shares") were granted to the following Directors and other persons discharging managerial responsibilities ("PDMRs") under the Company's LTIP, approved by shareholders on 22 July 2020.

Name	Director/ PDMR	Number of shares awarded under the LTIP1
Dr Carel Aron van der Merwe	Director	390 661
Petrus Jurgens Myburgh	Director	216 411
David John Hadley	PDMR	158 645
Gert Cornelis Hattingh	PDMR	83 946
Dr René Toua	PDMR	67 222
Magnus Oetiker	PDMR	125 538
Koert Hendrik Stefanus Pretorius	PDMR	87 651
Dr Dirk Cornelius le Roux	PDMR	65 787
Dr Daniel Liedtke	PDMR	156 076
Dr Tyson Bruno Welzel	PDMR	53 421

Note:

1

Directors' awards will be settled in shares upon vesting, and will be subject to a further two-year holding period. Awards granted to other PDMRS will be settled in cash upon vesting, also based on the average of the middle-market quotations of a share during a period of five dealing days ending with the dealing day before the day of vesting.

The awards made under the LTIP were granted for nil consideration and are based on the average of the middle-market quotations of a share during a period of five dealing days ending with the dealing day before the day of grant, which equates to £2.75 per share.

 FY21 LTIP Performance Conditions

Performance condition measured	Weighting	Threshold (25% vesting)	Target (62.5% vesting)	Stretch (100% vesting)
Adjusted EPS for FY23 (pence)1	40%	25.0p	29.0p	33.0p
TSR ranked relative to constituents of the FTSE 250 Index excluding financial services and extraction (measured over three financial years)	25%	50th percentile	62.5th percentile	75th percentile
ROIC for final year (FY23)	25%	4.5%	5.0%	6.0%
Patient Experience Index	10%	Based on the consolidated score of the three divisions achievement over the performance period 2 .

Notes:

1	Continues to be measured on a constant currency basis.
2	Given the impact of COVID-19 on Patient Experience scores, the Committee is continuing to keep the approach to the measurement of this element of the plan under review. Further details on the approach will be set out in the 2021 Directors' Remuneration Report.

The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Carel Aron van der Merwe
2.	Reason for the notification
a)	Position / status	Group Chief Executive Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 390 661
d)	Aggregated information Aggregated volume Price	390 661 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Petrus Jurgens Myburgh
2.	Reason for the notification
a)	Position / status	Group Chief Financial Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 216 411
d)	Aggregated information Aggregated volume Price	216 411 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	David John Hadley
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Mediclinic Middle East
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 158 645
d)	Aggregated information Aggregated volume Price	158 645 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Gert Cornelis Hattingh
2.	Reason for the notification
a)	Position / status	Group Chief Governance Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 83 946
d)	Aggregated information Aggregated volume Price	83 946 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr René Toua
2.	Reason for the notification
a)	Position / status	Group Chief Clinical Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 67 222
d)	Aggregated information Aggregated volume Price	67 222 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Magnus Oetiker
2.	Reason for the notification
a)	Position / status	Group Chief Strategy and Human Resources Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 125 538
d)	Aggregated information Aggregated volume Price	125 538 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Koert Hendrik Stefanus Pretorius
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Mediclinic Southern Africa
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 87 651
d)	Aggregated information Aggregated volume Price	87 651 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Dirk Cornelius le Roux
2.	Reason for the notification
a)	Position / status	Group Chief Information Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 65 787
d)	Aggregated information Aggregated volume Price	65 787 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Daniel Liedtke
2.	Reason for the notification
a)	Position / status	Chief Executive Officer: Hirslanden
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 156 076
d)	Aggregated information Aggregated volume Price	156 076 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Tyson Bruno Welzel
2.	Reason for the notification
a)	Position / status	Group Chief Innovation Officer -Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 53 421
d)	Aggregated information Aggregated volume Price	53 421 £nil
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	Outside a trading venue

 

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 September 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 17 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 11 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-2022.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6^th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHGCBDDXSBDGGU